Research programme: trypanosomiasis therapies - Anacor/DNDi/SCYNEXIS

Drug Profile

Research programme: trypanosomiasis therapies - Anacor/DNDi/SCYNEXIS

Alternative Names: AN-2920; AN-3520; AN-4169; SCYX-1330682; SCYX-1608210; SCYX-6759

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Anacor Pharmaceuticals; Drugs for Neglected Diseases Initiative Foundation; SCYNEXIS
  • Class Benzamides; Organic boron compounds; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Trypanosomiasis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Trypanosomiasis in USA (PO)
  • 24 Jun 2016 Anacor Pharmaceuticals has been acquired by Pfizer
  • 30 Jun 2011 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top